<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645810</url>
  </required_header>
  <id_info>
    <org_study_id>RGUP20045</org_study_id>
    <nct_id>NCT04645810</nct_id>
  </id_info>
  <brief_title>A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence</brief_title>
  <official_title>A Pilot Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR)&#xD;
      brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigator would like to better understand the use of high-dose rate&#xD;
      (HDR) brachytherapy to target only recurrent prostate cancer that can be seen by AXUMIN PET&#xD;
      scan. The use of HDR brachytherapy for prostate cancer is not new, but it is a more recent&#xD;
      advancement to use it to treat only what can be seen instead of the whole prostate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with prostate-specific antigen (PSA) levels rising of 2ng/ml or above</measure>
    <time_frame>6 Months</time_frame>
    <description>Rate of prostate-specific antigen (PSA) failure after focal salvage HDR in the setting of prostate only recurrence after primary non-surgical treatment, defined as a PSA rise of 2 ng/ml or more above the nadir at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events [Safety and Tolerability]</measure>
    <time_frame>6 Months</time_frame>
    <description>Measured by adverse event severity and quantity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 Months</time_frame>
    <description>Measure of time from study enrollment until progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>HDR</condition>
  <arm_group>
    <arm_group_label>Experimental: High-Dose-Rate prostate brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose-Rate brachytherapy, 2 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High-Dose-Rate Brachytherapy</intervention_name>
    <description>High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion</description>
    <arm_group_label>Experimental: High-Dose-Rate prostate brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        History of histologically confirmed, clinically localized adenocarcinoma of the prostate&#xD;
        treated with external beam radiation, brachytherapy, or combination of external beam&#xD;
        radiation and brachytherapy, with curative intent completed at least 24 months ago F-18&#xD;
        fluciclovine (AXUMIN) PET scan within 90 days prior to registration demonstrating recurrent&#xD;
        lesion within the prostate gland Biopsy confirmation of disease recurrence within the&#xD;
        prostate gland Age ≥ 18 KPS ≥ 70% Suitable candidate for brachytherapy based on established&#xD;
        criteria IPSS score &lt;16 No pelvic arch interference No Rectal fistula/fissure Fit for&#xD;
        general or spinal anesthesia No history of urethral stricture Ability to understand, and&#xD;
        willingness to sign the written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Evidence of metastatic or nodal disease outside of the prostate gland on AXUMIN PET scan&#xD;
        within 90 days prior to enrollment Patient unable to have MRI Patients with neuroendocrine&#xD;
        or small cell carcinoma of the prostate TURP within 6 months prior to enrollment History of&#xD;
        Crohn's disease, ulcerative colitis, or known radiation proctitis Inability to understand&#xD;
        spoken and written English&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester Wilmot Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Huggins</last_name>
    <phone>585-275-5973</phone>
    <email>Christine_Huggins@URMC.Rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Huggins</last_name>
      <phone>585-275-5973</phone>
      <email>Christine_Huggins@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Hong Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Hong Zhang</investigator_full_name>
    <investigator_title>Associate Professor - Department of Radiation Oncology (SMD)</investigator_title>
  </responsible_party>
  <keyword>Brachytherapy</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>High-Dose-Rate (HDR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

